Difference between revisions of "Template:Team:Utrecht/MainBody"

Line 971: Line 971:
 
<script id="page-secretion" type="text/template">
 
<script id="page-secretion" type="text/template">
 
<div class="page-heading">Secreting functional Cas9 and Cpf1</div>
 
<div class="page-heading">Secreting functional Cas9 and Cpf1</div>
In order to realize OUTCASST it is crucial to verify the activity of the two DNA-sensing elements. In our system, these are Cas9 and Cpf1. This experiment is a novelty in itself. To put the gravity of this experiment into perspective, as of today, there is no evidence of catalytically active secreted Cas9 or Cpf1.  
+
 
 +
In the OUTCASST system, our two DNA-sensing elements (dCas9 and dCpf1) are extracellularly fused to transmembrane proteins (see <a onclick="return change_page('outcasst', 1)" href="outcasst">OUTCASST system production</a>).
 +
However, for proteins to reach the cell membrane, they have to pass through the Endoplasmic Reticulum and the Golgi apparatus <i class="ref" data-id="1">1</i>. The chemical environment inside these organelles differs greatly from that of the cytosol. This includes the possibility of glycosylation and disulfide bond formation to occur. For a functional OUTCASST, dCas9 and dCpf1 need to be able to pass through the secretion pathway, and still be able to bind gRNA complementary DNA afterwards.  
  
 
<br><br>
 
<br><br>
 
<h2 class="subhead" id="subhead-2">Introduction</h2>
 
<h2 class="subhead" id="subhead-2">Introduction</h2>
In this experiment, we aim to secrete the two extracellular protein domains of the OUTCASST two-component fusion-protein system, Cas9 and Cpf1, and subsequently prove their functionality. This is a critical step in the process as the proteins should have the ability to bind DNA when implemented as the extracellular domains of OUTCASST. We conducted this experiment by creating genes for secretable Cas9 and Cpf1, using the same signal tag that is also used for the eventual OUTCASST proteins. These genes were inserted into bacterial plasmids, which were multiplied and transfected to mammalian cells. The protein was collected, purified and tested for functionality. If these products prove to be fully functional, they can be implemented in the final design.  
+
With these experiment, we aim to make HEK293t cells secrete Cas9 and Cpf1 into their growth medium. Subsequently, we will purify these secreted proteins and attempt to verify that they are still functional by performing an endonuclease assay. The proteins have maintained their DNA binding and cleaving capabilities if the proteins are still able to cut DNA strands in the correct place. If this is so, the catalytically inactive versions that form OUTCASST’s extracellular domains can be used in the final system, for we can then be sure that the secretory pathway does not disturb its DNA binding properties.
  
 
<br><br>
 
<br><br>
<h2 class="subhead" id="subhead-3">Methods</h2>
 
  
SECTION 1: CREATING THE DNA CONSTRUCTS
+
To get the proteins into the ER, an N-terminal signal peptide sequence needs to be introduced to the protein coding sequence. For this, the Ig lambda-2 chain V region signal sequence will be used, which is also used by Daringer et al. in their Modular Extracellular Sensor Architecture <i class="ref" data-id="2">2</i>.
 +
<br><br><b>LINK (head) to MESA</b>
 +
 
 
<br><br>
 
<br><br>
The DNA sequences coding for Cas9 or Cpf1 were modified to contain an N-terminal signal sequence and a C-terminal His-tag. A kozak sequence was placed in front of the protein coding region. This was then placed in a backbone plasmid containing a CMV promotor.
+
 
 +
To be able to purify the secreted proteins from growth medium, a C-terminal His-tag with glycine linker (GGGHHHHHH) was added. Using this, it would be possible to purify the proteins using Ni-NTA affinity chromatography. Cas9 and Cpf1 containing the signal sequence and His-tag will henceforth be referred to as sCas9 and sCpf1, respectively.
 +
 
 
<br><br>
 
<br><br>
<b>AsCpf1:</b>
+
<h2 class="subhead" id="subhead-3">Methods</h2>
<ol>
+
<li>PCR was performed using the following plasmid and primers, to create a fragment containing Cpf1 with a C-terminal Histag and overlap region for the final backbone plasmid <a target=_BLANK href="https://static.igem.org/mediawiki/2017/b/b4/Cpf1_PCR_protocol.pdf" class="pdf pdf-inline"></a>.<br>
+
<pre style="margin-top: 10px;">Plasmid: Lenti-AsCpf1-Blast (from Addgene, nr: 84750)
+
Fw primer 5’-3’: TCATCGAGGAGGACAAGGCCC
+
Rv primer 5’-3’: GCCGCTTACTTGTACTTAATGATGATGATGATGATGGCCG CCGCCGTTGCGCAGCTCCTGGATGTAG</pre><br>
+
</li>
+
<li>gBlock containing a kozak sequence, signal sequence and overlap regions with the backbone and Cpf1 was ordered from IDT. See snapgene file below for sequence.</li>
+
<li>In-Fusion Cloning was then performed using AgeI and BsrGI to linearize the backbone plasmid and the two previously created fragments <a target=_BLANK href="https://static.igem.org/mediawiki/2017/c/c9/UU_InFusion_protocol_v2.pdf" class="pdf pdf-inline"></a>.<br>
+
<pre style="margin-top: 10px;">Plasmid: pCAGGS_eGFP</per><br>
+
</li>
+
</ol>
+
  
 +
<b>Secretion, glycosylation and disulfide bond prediction</b>
 
<br>
 
<br>
 +
The signal sequence and His-tag were attached to Cas9 and Cpf1 in silico. The amino acid sequences were entered into the SignalP 4.1 server <i class="ref" data-id="3">3</i> to predict where the signal sequence would be cleaved off.
  
<b>Cas9:</b>
+
<br><br>
<ol>
+
 
<li>PCR was performed using the following plasmid and primers, to create a fragment containing Cas9 with a C-terminal Histag and overlap region for the final backbone plasmid <a target=_BLANK href="https://static.igem.org/mediawiki/2017/c/cd/UU_Cas9_PCR_protocol.pdf" class="pdf pdf-inline"></a>.<br>
+
The amino acids sequences were also entered in the NetNGlyc 1.0 Server <i class="ref" data-id="4">4</i>, which predicts N-glycosylation sites based on the known motif (Asn-X-Ser/Thr-Ser/Thr), and also on the DiANNA 1.1 web server <i class="ref" data-id="5">5</i>, to highlight the cysteines and their likelihood to form disulfide bonds.
<pre style="margin-top: 10px;">Plasmid: Lenti-Cas9-Blast (from Addgene, nr: 52962)
+
Fw primer 5’-3’: ATTCAAGGTGCTGGGCAACAC
+
Rv primer 5’-3’: GCCGCTTACTTGTACTTAATGATGATGATGATGATGGCCG CCGCCGTCGCCTCCCAGCTGAGACA</pre><br>
+
</li>
+
<li>PCR was performed to create a second fragment containing a kozak region, the signal sequence and the first part of Cas9 (without its methionine) <a target=_BLANK href="https://static.igem.org/mediawiki/2017/8/81/UU_-_PCR_Cas9_gBlock.pdf" class="pdf pdf-inline"></a>.<br>
+
<pre style="margin-top: 10px;">Plasmid: Lenti-Cas9-Blast (from Addgene)
+
Fw primer 5’-3’: CCCGGGATCCACCGGTGCCGCCACCATGGCGTGG ACCAGCCTGATTCTGAGCCTGCTGGCGCTGTGCAGCGGCGCGAGCAGCG ACAAGAAGTACAGCATCGGCCTG
+
Rv primer 5’-3’: CCCAGCACCTTGAATTTCTTGCTG</pre><br>
+
</li>
+
<li>In-Fusion Cloning was then performed using AgeI and BsrGI to linearize the backbone plasmid and the two previously created fragments <a target=_BLANK href="https://static.igem.org/mediawiki/2017/c/c9/UU_InFusion_protocol_v2.pdf" class="pdf pdf-inline"></a>.<br>
+
<pre style="margin-top: 10px;">Plasmid: pCAGGS_eGFP</pre><br>
+
</li>
+
</ol>
+
  
 
<br><br>
 
<br><br>
  
SECTION 2: TRANSFECTION INTO HEK293T CELLS<br>
+
The predicted N-glycosylation sites were marked on crystal structures of both Cas9 and Cpf1 using PyMol <i class="ref" data-id="6">6</i> to get a clear image of where these sites would be and to clarify the likelihood that glycosylation would disturb protein functionality.
HEK293t cells were cultured according to the cell culture protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/2/2e/UU_Cell_culture_protocol.pdf" class="pdf pdf-inline"></a>. We transfected the cells with the midiprepped plasmids according to the Lipofectamine 2000 transfection protocol [Experimental\Protocols\Wiki ready\Lipofectamine 2000 transfection protocol.pdf].
+
For protein purification under denaturing conditions, HEK cells in 6 wellplate wells were transfected. For protein purification under native conditions, HEK cells in 10 cm petridishes were cotransfected (9:1 plasmid of interest : plasmid containing GFP).  
+
  
 
<br><br>
 
<br><br>
SECTION 3: PROTEIN PURIFICATION UNDER DENATURING CONDITIONS<br>
+
 
Secreted and His-tagged Cas9 and Cpf1, which will be referred to as sCas9 and sCpf1, respectively, were purified from the medium using Ni-bead purification, according to protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/4/41/Purification_of_cells_and_medium_secreted_cpf1_and_cas9.pdf" class="pdf pdf-inline"></a>. Also, whole-cell lysates were made, following the same protocol, to check for possible accumulation of sCas9 or sCpf1 in HEK293t cells.
+
<b>Creating the DNA constructs</b>
 +
<br>
 +
DNA sequences coding for Cas9 and Cpf1 were modified to contain an N-terminal signal sequence (removing the first methionine from Cas9 and Cpf1) and a C-terminal His-tag. A kozak sequence was placed in front of the protein coding region, to help initiate the translation process in mammalian cells. This was then placed in a backbone plasmid (pCAGGS). These plasmids were subsequently amplified in <i>E. coli</i>. See the supplementary information for cloning procedures and plasmid sequences.
  
 
<br><br>
 
<br><br>
SECTION 4: VERIFYING THE PRESENCE OF HIS-TAGGED PROTEINS IN THE MEDIUM<br>
+
<b>HEK293t transfection</b>
The presence of sCas9 and sCpf1 was verified using SDS-PAGE and Western Blots. Proteins were separated using SDS-PAGE using the following protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/a/ab/General_Protocol_SDS-PAGE_Western_Blot.pdf" class="pdf pdf-inline"></a>.  
+
<br>
10% acrylamide running gels, and stacking gels were made according to the following protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/b/b1/Preparing_SDS-PAGE_gels.pdf" class="pdf pdf-inline"></a>. Western Blots were carried out according to the same protocol as for the SDS-PAGE.
+
HEK293t cells were cultured according to our cell culture protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/2/2e/UU_Cell_culture_protocol.pdf" class="pdf pdf-inline"></a>.  
The secreted proteins were incubated with mouse anti-His6x (using dilutions of 1:2000 and 1:5000) and rabbit anti-Cas9 or rabbit anti-Cpf1 (using dilutions of 1:2000). The secondary antibody was a goat anti-mouse for the Histag and goat anti-rabbit for both Cas9 and Cpf1, with a horseradish peroxidase (HRP) conjugate to verify the presence of secreted proteins.  
+
The cells were transfected with plasmids according to the Lipofectamine 2000 transfection protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/1/17/UU_-_Lipofectamine_2000_transfection_protocol.pdf" class="pdf pdf-inline"></a>.
  
 
<br><br>
 
<br><br>
SECTION 5: PROTEIN PURIFICATION UNDER NATIVE CONDITIONS<br>
 
Proteins were purified using Ni-NTA superflow columns, according to the following protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/f/fa/UU_Ni-NTA_superflow_colums_protocol.pdf" class="pdf pdf-inline"></a>. No imidazole in the pre- and washing buffers was used. Additionally, 50 ul samples were taken of the pellet, supernatant, filtered supernatant, and the runthrough.
 
Whole cell lysates were made using protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/4/41/Purification_of_cells_and_medium_secreted_cpf1_and_cas9.pdf" class="pdf pdf-inline"></a> to check for possible accumulation of sCas9 or sCpf1 in Hek293t cells.
 
  
 +
<b>Verifying the presence of secreted proteins</b>
 +
<br>
 +
Medium and cells were harvested three days after transfection.
 +
Protein from the medium and cell lysates were purified under denaturing conditions using Ni-bead purification,
 +
according to a purification protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/4/41/Purification_of_cells_and_medium_secreted_cpf1_and_cas9.pdf" class="pdf pdf-inline"></a>.
 +
In a duplicate experiment, protein from medium and cell lysate was purified under native conditions according to a
 +
different purification protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/c/cc/UU_-_purifying_under_native_conditions.pdf" class="pdf pdf-inline"></a>.
 +
 +
<br><br>
 +
The presence of sCas9 and sCpf1 in medium, cell lysate and after purification steps was verified with SDS-PAGE and Western Blots.
 +
Proteins were separated using SDS-PAGE using a standard SDS-PAGE and blotting protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/a/ab/General_Protocol_SDS-PAGE_Western_Blot.pdf" class="pdf pdf-inline"></a>.
 +
Polyacrylamide running and stacking gels were made according to standard recipes <a target=_BLANK href="https://static.igem.org/mediawiki/2017/b/b1/Preparing_SDS-PAGE_gels.pdf" class="pdf pdf-inline"></a>.
 +
Western Blots were carried out according to the same procedure as SDS-PAGE.
 +
<br><br>
 +
Subsequently, the blotting membranes were incubated with anti-his antibodies originating from a mouse at 1:2000 dilution or with anti-Cas9 and anti-Cpf1 antibodies,
 +
both originating from rabbit, also at 1:2000 dilution.
 +
Secondary antibodies containing a horseradish peroxidase (HRP) conjugate (1:10 000 dilution) were used to verify the presence of
 +
secreted proteins by the detection of chemiluminescence.
 +
<br><br>
 +
Additionally, together with team Wageningen_UR a final experiment was done to verify that the protein in the medium was indeed secreted instead of due to involuntary cell lysis (see <a onclick="return change_page('collaborations', 1)" href="collaborations">Collaborations</a>).
 +
This experiment was done in duplo, by members from both team Wageningen_UR and team Utrecht, individually, to provide independent verification of the result. This final experiment was done according to a collaboration protocol that was shared with the Wageningen_UR team [Experimental\Protocols\Wiki ready\Experimental\Protocols\Wiki ready.pdf].
 +
<br><br>
 +
<b>Endonuclease activity assay</b>
 +
<br>
 +
An in vitro endonuclease activity assay was performed twice; first using purified Cas9 and Cpf1 (supplied to us by Geijsen lab),
 +
to test which gRNA concentrations are optimal for the assay. The second endonuclease activity assay was performed using purified sCas9 and sCpf1, as well as Cas9 and Cpf1.
 +
<br><br>
 +
Cas9 gRNA was prepared from DNA oligos according to a gRNA production protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/8/8d/UU_-_Nuclease_activity_assay_-_Cas9_gRNA_production.pdf" class="pdf pdf-inline"></a>.
 +
Cpf1 gRNA was ordered from IDT, as it proved too short for synthesis according to the aforementioned protocol. A linearized plasmid of approximately 800 base pairs was used as template, with sRNAs complementary to roughly the same region of the linearized plasmid. This would result in two cut fragments of ~260 base pair and ~560 base pair lengths for both Cas9 and Cpf1 cleavage.
 
<br><br>
 
<br><br>
SECTION 6: IN VITRO ENDONUCLEASE ACTIVITY ASSAY<br>
+
The first assay was performed according to protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/1/12/Nuclease_activity_assay_-_assay_UU.pdf" class="pdf pdf-inline"></a>. An adjusted protocol was used for the second assay, due to low concentrations of purified sCas9 and sCpf1 <a target=_BLANK href="https://static.igem.org/mediawiki/2017/1/13/UU_-_Nuclease_activity_assay_-_assay2.pdf" class="pdf pdf-inline"></a>. See the supplementary information for cloning procedures and sequences.
After successful purification of sCas9-His6x and sCpf1-His6x and subsequent verification of the presence of the aforementioned proteins, an in vitro endonuclease activity assay was carried out. The in vitro endonuclease activity assay was used to assess whether or not our secreted and, in all likelihood, glycosylated sCas9-His6x and sCpf1-His6x would still exhibit sgRNA-binding- and endonuclease activity. The assay was executed according to the protocol <a target=_BLANK href="https://static.igem.org/mediawiki/2017/1/12/Nuclease_activity_assay_-_assay_UU.pdf" class="pdf pdf-inline"></a>.  
+
Linearized plasmid 51-dPAM (823 bp) <a target=_BLANK href="https://static.igem.org/mediawiki/2017/3/3c/51_dPAM_800bp.zip" class="zip zip-inline"></a> was used as the target for sCas9-His6x and His6x-Cpf1. Two sgRNAs were used that were tailored to be bound by either Cas9 or Cpf1: <a target=_BLANK href="https://static.igem.org/mediawiki/2017/9/9d/SpCas9_gRNA1_Tet-luc.zip" class="zip zip-inline"></a> and <a target=_BLANK href="https://static.igem.org/mediawiki/2017/5/5e/Ascpf1_sgRNA.zip" class="zip zip-inline"></a>, respectively. Both sgRNAs were complementary to roughly the same region of the aforementioned linearized plasmid, which would result in two cut fragments of ~260 bp and ~560 bp for both His6x-Cas9 and His6x-Cpf1. The efficacy of these sgRNAs, both in binding to the target region in the linearized plasmid, and binding to either Cas9 or Cpf1 were also assessed. As positive controls we used unmodified Cas9 and Cpf1 produced by Escherichia coli, coupled with their respective sgRNAs and the linearized target plasmid. The negative controls consisted of the linearized plasmid with either Cas9 or Cpf1 without sgRNA, and a third negative control with the linearized plasmid only. Subsequently, the samples were separated by DNA gel electrophoresis.
+
  
 
<br><br>
 
<br><br>
 
<h2 class="subhead" id="subhead-4">Results</h2>
 
<h2 class="subhead" id="subhead-4">Results</h2>
  
SECTION 1: CREATING THE DNA CONSTRUCTS<br>
+
<b>Secretion, glycosylation and disulfide bond prediction</b>
As mentioned at the methods, the plasmid sequences and features can be viewed at:<br>
+
 
<br>
 
<br>
<img width="600" src="https://static.igem.org/mediawiki/2017/8/8e/Uuextra_figure1.png">
+
SignalP 4.1 predicted cleavage right after the signal sequence for both sCas9 and sCpf1. The results of the prediction can be found here <a target=_BLANK href="https://static.igem.org/mediawiki/2017/9/97/UU_-_SignalP_results.pdf" class="pdf pdf-inline"></a>.
<br>
+
<b>Snapgene file:</b> iGEM 2017\Experimental\SnapGene\Secreted Cas  or Cpf\  pCAGGS_sigseq_Cpf1_Histag.dna<br>
+
<br>
+
and<br>
+
<br>
+
<img width="600" src="https://static.igem.org/mediawiki/2017/3/3e/Uuextra_figure2.png"><br>
+
<b>Snapgene file:</b> iGEM 2017\Experimental\SnapGene\Secreted Cas  or Cpf\  pCAGGS_sigseq_Cas9_Histag.dna<br>
+
<br>
+
<b>Table 1. Nanodrop results of midiprepped plasmids</b>
+
<table width="450">
+
<tr>
+
<td><b>Plasmid</b></td>
+
<td><b>Concentration (ng/ul)</b></td>
+
</tr>
+
<tr>
+
<td>pCAGGs_sigseq_Cas9_Histag</td>
+
<td>809,7</td>
+
</tr>
+
<tr>
+
<td>pCAGGs_sigseq_Cpf1_Histag</td>
+
<td>1322</td>
+
</tr>
+
<tr>
+
<td>Lenti Cas9</td>
+
<td>2593,9</td>
+
</tr>
+
<tr>
+
<td>Lenti Cpf1</td>
+
<td>1312,7</td>
+
</tr>
+
</table>
+
 
<br><br>
 
<br><br>
 +
Six N-glycosylation motifs were detected in Cas9, of which five had a high probability of being N-glycosylated. In Cpf1, four motifs were detected, three of which had a high glycosylation probability.
 +
<br><br>
 +
<center><img style="margin-top: 10px;" src="https://static.igem.org/mediawiki/2017/4/4a/UU_fig1_-_Glycosylation_sites.PNG"></center>
 +
<span class="text-figure"><b>Figure 1. Glycosylations sites in Cas9 and Cpf1.</b> Predicted N-glycosylation sites are marked red in the crystal structures of Cas9 (PDB: 4OO8) and Cpf1 (PDB: 5B43). N-terminus is marked purple, C-terminus is marked yellow, gRNA is shown in orange and the bound DNA is shown in green.
 +
</span>
  
SECTION 2: TRANSFECTION INTO HEK293T CELLS
+
<br><br>
Lipofectamine 2000 has a high transfection efficiency and at the time no fluorescent microscope was available. Therefore we did not do a cotransfection of the plasmids with eGFP at the small batch (denaturing conditions). The transfection success was verified by the Western Blot results (See results of section 4?)
+
Two cysteines were marked as having a high chance of forming disulfide bonds in Cas9, while  eight such cysteines were found in Cpf1. Details can be found in the supplementary information.
 +
<br><br>
 +
<b>Creating the DNA constructs</b><br>
 +
All constructs were verified by sequencing.
 +
<br><br>
 +
<b>Verifying the presence of secreted proteins</b><br>
 +
<center><img style="margin-top: 10px; width: 400px;" src="https://static.igem.org/mediawiki/2017/c/cf/UU_fig2_-_western_under_denaturing_conditions.png"></center>
 +
<span class="text-figure"><b>Figure 2. Western Blot using protein purified under denaturing conditions.</b> A band at the correct height is present in the lanes containing purified sCas9 and sCpf1 from the medium, indicating presence of sCas9 and sCpf1 in the medium.
 +
</span>
 +
<br><br>
 +
Figure 2 shows the presence of sCas9 and sCpf1 in the medium, which indicated the proteins are secreted and that the experiment could be redone under native conditions but only small quantities of protein could be purified (~0,5 ng/uL in 0,5 mL for both sCas9 and sCpf1).
 +
<br><br>
 +
<center><img style="margin-top: 10px; width: 450px;" src="https://static.igem.org/mediawiki/2017/d/de/UU_fig3_-_western_under_native_conditions.png"></center>
 +
<span class="text-figure"><b>Figure 3. Western Blot using protein purified under native conditions.</b> The left image shows samples from cells transfected with a sCas9 containing plasmid, incubated with Anti-Cas9. The right image shows samples transfected with a sCpf1 containing plasmid, incubated with a Cpf1 antibody.The images suggest that sCas9 and sCpf1 are indeed secreted into the medium, though it cannot be excluded that part of the protein in the media is due to cell lysis.
 +
</span>
 +
<br><br>
 +
After newly expressing sCas9 and sCpf1 in HEK293t cells, blots of the Cpf1 protein (figure 4) displayed the presence of secreted Cpf1 in both medium and cell lysate. In the medium, two bands are shown, one with a lower mass than Cpf1 is supposed to have. This lower band is, ostensibly, a degradation product. In the cell lysate, we see a second band as well, this time of higher mass. We suspect that this band corresponds to glycosylation product that accumulates in the cells and cannot be secreted. The results from the Wageningen_UR team confirm the presence of sCpf1 in both cell lysate and medium, as expected, again showing a lower mass band for the protein in the medium.
 +
<br><br>
 +
<center><img style="margin-top: 10px;" src="https://static.igem.org/mediawiki/2017/0/0e/UU-secretion-fig4.png"></center>
 +
<span class="text-figure"><b>Figure 4. Secretion products of Cpf1.</b> The left image displays the blotting results of Utrecht’s team. The right image displays the blotting results of our Wageningen_UR collaborators. sCpf1 is shown on both blots, displaying two bands. Cell lysates of sCpf1 producing cells display sCpf1 as well.
 +
</span>
  
During transfection of the big batch (native conditions) we had a fluorescent microscope available and therefore the plasmids were cotransfected with eGFP (figure xa and xb).
+
<br><br>
  
<br>
+
<b>Endonuclease activity assay</b><br>
<img src="https://static.igem.org/mediawiki/2017/e/e1/Uutransfectionhekcells.png">
+
The first endonuclease activity assay was used to determine the optimal concentration of gRNA for the assay with the secreted proteins. The concentrations used were all functional for the Cpf1 protein (Figure 5). Cas9 however, showed no cleavage of the targeted DNA at all. This may be due to low quality gRNA. In the second assay, which contained sCas9 and sCpf1 purified from medium, there was no cleavage visible at all, even for the controls with Cas9 and Cpf1, as shown in figure 6.
<br>
+
<center><img style="margin-top: 10px;" src="https://static.igem.org/mediawiki/2017/f/fc/UU_secretion_fig5.png"></center>
Figure x. Fluorescent microscope image of HEK293t cells cotransfected with eGFP and pCAGGs_sigseq_Cas9_Histag (a) and pCAGGs_sigseq_Cpf1_Histag (b) (plasmid ratio 1:9). In both cases, eGFP expression is clearly visible, indicating successful cotransfections.
+
<span class="text-figure">
 +
<b>Figure 5.</b> Left - DNA gel electrophoresis of a linearized 800 base pair length plasmid. Concentrations of Cas9 and Cpf1 used in the assay were 0,05 uM and 0,15 uM, respectively. Right - DNA gel electrophoresis of the linearized 800bp plasmid. 2,5 nM Cas9 or Cpf1 protein was used and 10 nM gRNA.
 +
</span>
  
 
<br><br>
 
<br><br>
SECTION 3: PROTEIN PURIFICATION UNDER DENATURING CONDITIONS<br>
+
<h2 class="subhead" id="subhead-5">Discussion</h2>
<br>
+
The goal of this experiment was to create secretable Cas9 and Cpf1 and test the functionality of these proteins. We have a clear indication that we achieved in obtaining secretion product, demonstrated by figures 2,3 and the collaboration results. Even if cell death has contributed to the protein concentrations in the media at all, it seems unlikely that it could account for a majority of the product. This, in addition to the lack of cell debris in the culturing plates, leads us to believe that the proteins can indeed be secreted.
<img width="600" src="https://static.igem.org/mediawiki/2017/e/e7/Uuwestern.png">
+
<br><br>
<br>
+
As of yet, we have not been able to demonstrate nuclease activity for either sCas9 or sCpf1. In our nuclease assay with the secreted proteins, the substrate was not cleaved. Even the control proteins did not show cleavage, suggesting that something went wrong with the assay. This lack of cleavage could be due to the low concentrations of protein purification product. In this assay, the incubation time was increased in comparison to standard endonuclease assay protocols to compensate for the low purification yields. Poor quality gRNA could also have caused the lack of cleavage. For future research, we suggest gRNA verification is performed before the assay is attempted. Based on our predictions for glycosylation, it seems likely that sCas9 and sCpf1 are still enzymatically active, even though some optimization might be required to gain satisfactory cleavage efficiency.
figure x: Western blots of Cpf1 and Cas9, using anti-Cas9 and anti-Cpf1 antibodies. In both cases, the purified protein shows a band, suggesting the successful secretion of Cpf1 and Cas9.
+
<br><br>
 +
Versions of Cas9 and Cpf1 that can pass through the secretion pathway and maintain their DNA binding capabilities are essential for the OUTCASST system. The secretable sCas9 and sCpf1 proteins have merit on their own as well. A system where Cas9 and Cpf1 are made and secreted by mammalian cells could be useful for production of clinically usable endonucleases. Bacterial production may, at first glance, seem more straightforward but poses problems of clinical purity as bacterial endotoxins can easily contaminate the protein. Production of these proteins in mammalian cells could circumvent this problem.
 +
 
  
 
<br><br>
 
<br><br>
SECTION 4: ACTIVITY ASSAY<br>
+
<h2 class="subhead" id="subhead-6">References</h2>
<br>
+
 
<img src="https://static.igem.org/mediawiki/2017/5/54/Uuactivityassay1.png">
+
<ol class="references">
<br>
+
<li data-title="Molecular Cell Biology." data-author="Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology." data-link="https://www.ncbi.nlm.nih.gov/books/NBK21471/" /> Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 4th edition. New York: W. H. Freeman; 2000. Section 17.3, Overview of the Secretory Pathway. <a target=_BLANK href="https://www.ncbi.nlm.nih.gov/books/NBK21471/" class="url_external"></a>
Figure x. DNA gel electroforesis of the linearized 800bp 51_dPAM plasmid, cut by either normal  Cas9 or  normal Cpf1. Lanes from left to right are 1. ladder , 2. Cas9 + 0,5 uM gRNA, 3. Cas9 + 1 uM gRNA, 4.Cas9 + 2 uM gRNA, 5. Cas9 // no gRNA, 6. Cpf1 + 1 uM gRNA, 7. Cpf1 + 5 uM gRNA, 8. Cpf1 + 10 uM gRNA, 9. Cpf1 // no gRNA, 10. only plasmid. Concentration of Cas9 and Cpf1 used in the assay were 0,05 and 0,15, respectively. Red in the image is an artefact due to the software. As can be seen in lanes 6-8, normal Cpf1 cleaves
+
<li data-title="Modular Extracellular sensor architecture for engineering mammalian cell-based devices." data-author="Daringer, N. M., Dudek, R. M., Schwarz, K. A., & Leonard, J. N." data-link="https://doi.org/10.1021/sb400128g" /> Daringer, N. M., Dudek, R. M., Schwarz, K. A., & Leonard, J. N. (2014). Modular Extracellular sensor architecture for engineering mammalian cell-based devices. ACS Synthetic Biology, 3(12), 892–902. <a target=_BLANK href="https://doi.org/10.1021/sb400128g" class="url_external"></a>
<br>
+
<li data-title="SignalP 4.0: discriminating signal peptides from transmembrane regions." data-author="Petersen, T.N., Brunak, S., Von Heijne, G. & Nielsen, H." data-link="http://www.cbs.dtu.dk/services/SignalP/" /> Petersen, T.N., Brunak, S., Von Heijne, G. & Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nature Methods, 8:785-786, 2011. <a target=_BLANK href="http://www.cbs.dtu.dk/services/SignalP/" class="url_external"></a>
<br>
+
<li data-title="Prediction of N-glycosylation sites in human proteins." data-author="Gupta, R., Jung, E. and Brunak, S." data-link="http://www.cbs.dtu.dk/services/NetOGlyc/" /> Gupta, R., Jung, E. and Brunak, S. Prediction of N-glycosylation sites in human proteins. In preparation, 2004. <a target=_BLANK href="http://www.cbs.dtu.dk/services/NetOGlyc/" class="url_external"></a>
<img src="https://static.igem.org/mediawiki/2017/3/39/Nocleavagedetected.png">
+
<li data-title="DiANNA 1.1: an extension of the DiANNA web server for ternary cysteine classification." data-author="Ferre, F. & Clote, P." data-link="http://clavius.bc.edu/~clotelab/DiANNA/" /> Ferre, F. & Clote, P. DiANNA 1.1: an extension of the DiANNA web server for ternary cysteine classification. Accepted for publication in Nucleic Acids Res. - Web Servers 2006 special issue. <a target=_BLANK href="http://clavius.bc.edu/~clotelab/DiANNA/" class="url_external"></a>
<br>
+
<li data-title="The PyMOL Molecular Graphics System." data-author="Schrödinger, LLC." data-link="https://pymol.org/2/" /> The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. <a target=_BLANK href="https://pymol.org/2/" class="url_external"></a>
Figure x:
+
</ol>
 +
 
 +
<span id="tooltip-1"></span>
 +
<span id="tooltip-2"></span>
 +
<span id="tooltip-3"></span>
 +
<span id="tooltip-4"></span>
 +
<span id="tooltip-5"></span>
 +
<span id="tooltip-6"></span>
 +
 
  
 
<br><br>
 
<br><br>
<h2 class="subhead" id="subhead-5">Discussion</h2>
+
<h2 class="subhead" id="subhead-7">Supplementary</h2>
&hellip;
+
 
 +
<a target=_BLANK href="https://static.igem.org/mediawiki/2017/c/c2/UU_-_Supplementary_info_-_Secreting_functional_Cas9_and_Cpf1.pdf" class="pdf">Supplementary information - Secreting functional Cas9 and Cpf1.</a>
 +
 
 
</script>
 
</script>
  
Line 3,191: Line 3,205:
 
3: "Methods",
 
3: "Methods",
 
4: "Results",
 
4: "Results",
5: "Discussion"
+
5: "Discussion",
 +
6: "References",
 +
7: "Supplementary"
 
},
 
},
 
"mesa-replication" : {
 
"mesa-replication" : {

Revision as of 13:15, 1 November 2017

<!DOCTYPE html>

Cas9 & Cpf1 secretion
and activity
Comparison of endonuclease activity for Cas9 and Cpf1 that has been produced in, and excreted by, HEK293 cells.
MESA two-component system replication
Details on the MESA two-component system, explanation of its relation to our design and the results of its reproduction.
OUTCASST system production
Detailed explanation of the OUTCASST mechanism, experimental progress and technical prospects.
Modeling and
mathematics
Ordinary differential equations, cellular automaton and an object based model for optimal linker-length estimation.
InterLab study participation
Results and details of our measurements for the iGEM 2017 InterLab Study.
Stakeholders & opinions
Interviews and dialogues with stakeholders, potential users, third parties and experts relating to pathogen detection or DNA-based diagnostics.
Risks & safety-issues
Implications and design considerations relating to safety in the usage and implementation of OUTCASST as a diagnostics tool.
Design & integration
OUTCASST toolkit and product design with factors such as bio-safety and user-friendliness taken into account.
Outreach
Videos we made for the dutch public, together with 'de Kennis van Nu'.
Meet our team
About us, our interests and roles in the team and our supervisors.
Sponsors
A listing of our sponsors, how they assisted us and our gratitude for their assistance.
Collaborations
Read about our exchanges with other iGEM teams and government agencies.
Achievements
A short description of all that we have achieved during our participation in the iGEM.
Attributions
A thank-you for everyone that assited us, both in and outside the lab.